...
首页> 外文期刊>MIMS Doctor. >Ustekinumab shows durable responses in adults with Crohn's disease
【24h】

Ustekinumab shows durable responses in adults with Crohn's disease

机译:Ustekinumab显示持久的反应成人克罗恩氏病

获取原文
获取原文并翻译 | 示例
           

摘要

Induction therapy with the human IgGiK* monoclonal antibody ustekinumab led to sustained clinical remission in patients with moderate-to-severe Crohn's disease (CD), according to the extension phase results of the IM-UNITI** study presented at the 2019 Crohn's & Colitis Congress. This phase III trial included two multicentre 8-week induction studies (ie, UNITI 1 and 2) comprising 1,281 participants. Individuals who achieved clinical remission at week 8 (reductions in Crohn's Disease Activity Index [CDAI] >100 points) were randomized 1:1:1 to receive ustekinumab 90 mg either every 8 (q8w) or 12 weeks (q12w), or placebo. [2019 Crohn's & Colitis Congress, abstract P034]
机译:诱导治疗与人类IgGiK *单克隆抗体ustekinumab导致持续的临床缓解患者的严重克罗恩病(CD),根据扩展阶段IM-UNITI * *研究的结果国会在2019年克罗恩氏和结肠炎。三期临床试验包括两个多中心8周归纳研究(即UNITI 1和2)组成1281名参与者。8周后临床缓解期(减少克罗恩病活动指数(CDAI) > 100分)被随机分配比ustekinumab 90毫克每8 (q8w)或12周(q12w)或安慰剂。国会、抽象P034]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号